Presymptom Health was established in 2019 to apply cutting edge machine learning and AI analytics to derive insights from a fully-annotated 72,000-sample biobank to detect infection and sepsis in patients up to three days before symptoms appear.
Presymptom is focused on the development of clinical diagnostic tests and associated clinical decision-support software to rule out the presence of infection and sepsis. The company’s tests currently in development will:
The company’s products, which focus on host response assessment, have been discovered and are being tested in clinical trials collectively encompassing over 6,000 patients across 7 studies in support of fulfilling Presymptom’s vision of delivering high-impact tests for use at both point-of-care and within central laboratory settings.
Presymptom will secure first regulatory clearance for its products in 2025.
21 March 2024
14 February 2024
20 September 2023
8 September 2023